Fierce Pharma Asia—China’s IIT scrutiny; Daiichi Sankyo, AZ ph. 3 win; Leo, Tanabe’s dermatology deal
China’s investigator-initiated trials, once praised for their speediness, have been drawn into scrutiny for a lack of transparency.…
GSK CEO targets $2.5B in cost savings from mature products, procurement, supply chain
About half a year into his tenure as GSK’s CEO, Luke Miels is launching a three-year restructuring to…
Lilly’s long-acting insulin wins NICE blessing ahead of potential UK approval
For patients living with Type 2 diabetes in the United Kingdom, a more convenient treatment option may be…
AstraZeneca touts Enhertu, Orpathys dual lung cancer wins amid bispecific failure
AstraZeneca reported positive results from two non-small cell lung cancer trials for Enhertu and an Orpathys-Tagrisso combination, although…
GSK to seek FDA approval for Jemperli in high-profile cancer use
In what GSK says represents a potential way to transform treatment for patients with certain types of rectal…
AZ’s blood pressure newcomer Baxfendy fails to meet cost-effectiveness bar, ICER says
AstraZeneca’s newly approved, first-in-class hypertension drug Baxfendy does not clear the bar for effectiveness relative to its price,…
AstraZeneca settles Texas kickback lawsuit, agreeing to pay $34M
AstraZeneca will pay $34 million to resolve a lawsuit that alleged the company used illegal kickbacks to induce…
Editor’s Corner: Why an AZ-BMS merger would be a very bad idea
It’s been years since Big Pharma last witnessed a megamerger. In the late 2010s, Takeda bought Shire, AbbVie…
‘No discussions’ ongoing for AstraZeneca-BMS merger: Reuters
AstraZeneca and Bristol Myers Squibb do not have any ongoing discussions about a potential deal, Reuters reported Wednesday,…
AstraZeneca, CSPC to form manufacturing joint venture
AstraZeneca and CSPC Pharmaceutical are strengthening their partnership by establishing a new biologics manufacturing joint venture in China. …
Nuvalent deal delivers GSK’s first-ever lung cancer approval
In a landmark moment for its oncology ambitions, GSK has secured FDA approval for Jideytro (zidesamtinib) as the…
GSK shares rally on parent company news and retail momentum; other pharma firms follow
Pharma giant GSK Egypt’s stock briefly touched a record EGP 609 yesterday before cooling off to close 5.77%…